<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1300">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751669</url>
  </required_header>
  <id_info>
    <org_study_id>CoVIT Clinical Trial</org_study_id>
    <nct_id>NCT04751669</nct_id>
  </id_info>
  <brief_title>Efficacy of a Dietary Supplementation in Reducing Hospital Admissions for COVID-19. Randomized Clinical Trial</brief_title>
  <acronym>CoVIT</acronym>
  <official_title>Efficacy of Micronutrient Dietary Supplementation in Reducing Hospital Admissions for COVID-19: A Double-blind, Placebo-controlled, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut Germans Trias i Pujol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut Germans Trias i Pujol</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo-controlled, randomized clinical trial to assess efficacy of&#xD;
      micronutrient dietary supplementation in reducing hospital admissions for COVID-19.&#xD;
&#xD;
      We want to assess the need for hospital admission for severe acute respiratory syndrome&#xD;
      Corona Virus-2 (SARS-CoV-2) infection in outpatients diagnosed of COVID-19 disease, taking a&#xD;
      micronutrient supplementation for 14 days. The outcome Will be measured within 1 month after&#xD;
      beginning the study treatment. The patients will be followed-up for a period of 90 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Type of study/ Design: Randomized, double-blind, placebo-controlled clinical trial.&#xD;
&#xD;
        -  Sponsor: Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol /&#xD;
           Hospital Universitari Germans Trias i Pujol ( IGTP / HUGTIP)&#xD;
&#xD;
        -  Title of the clinical trial: Efficacy of micronutrient dietary supplementation in&#xD;
           reducing hospital admissions for COVID-19: A double-blind, placebo-controlled,&#xD;
           randomized clinical trial.&#xD;
&#xD;
        -  Protocol code: CoVIT Clinical Trial&#xD;
&#xD;
        -  NºClinicaltrials.gov: Pending&#xD;
&#xD;
        -  Coordinating researcher: Dra. Teresa-Maria Tomasa-Irriguible.&#xD;
&#xD;
        -  Recruiting Center: Germans Trias i Pujol University Hospital (HUGTIP)&#xD;
&#xD;
        -  Ethical Committee for clinical Investigation (CEI): Germans Trias i Pujol University&#xD;
           Hospital CEI.&#xD;
&#xD;
        -  Monitoring: Clinical Research Associate at UPIC (Unitat Polivalent d'Investigació&#xD;
           Clínica) Clinical Trial Unit- IGTP&#xD;
&#xD;
        -  Study treatments: Dietary supplement with micronutrients and Placebo&#xD;
&#xD;
        -  Test phase: Not applicable.&#xD;
&#xD;
        -  Main objective: Evaluation of the effectiveness of supplementation with a dietary&#xD;
           supplement to improve the need for hospital admission for SARS-CoV-2 infection.&#xD;
&#xD;
        -  Study pathology: COVID-19.&#xD;
&#xD;
        -  Main variable: The need for hospital admission of SARS-CoV-2 documented infection&#xD;
&#xD;
        -  Study population and total number of patients: Patients of the health system of the&#xD;
           Northern Metropolitan Area of Catalan Health Institution with symptoms compatible with&#xD;
           SARS-CoV-2 infection. A total of 300 people (150 treated with dietary supplement and 150&#xD;
           with placebo).&#xD;
&#xD;
        -  Duration of treatment: 14 days.&#xD;
&#xD;
        -  Patients follow-up: 90 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A double-blind, placebo-controlled, randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo tablets with the same external aspect than the dietary supplement, the same administration route, containing only the excipients</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Need for hospital admission</measure>
    <time_frame>From baseline to 1 month after beginning the study treatment</time_frame>
    <description>The need for hospitalization of documented SARS-CoV-2 infection (positive polymerase chain reaction or transcription-mediated amplification test or antigen test or positive serology or diagnostic test available) over the course of the disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Micronutrient basal status</measure>
    <time_frame>Within day 1 at study inclusion</time_frame>
    <description>Evaluation of micronutrient status prior to the nutritional supplement administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micronutrient status at hospital admission</measure>
    <time_frame>Within the first day of hospital admission</time_frame>
    <description>Evaluation of micronutrient status in patients requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micronutrient status at end of study</measure>
    <time_frame>Within 90 days of the study treatment ending</time_frame>
    <description>Evaluation of micronutrient status after the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameters</measure>
    <time_frame>From baseline to 30 days of the study treatment ending</time_frame>
    <description>Evaluation of C-Reactive Protein, InterLeukin-6 and D-dimer progression during the clinical course of SARS-CoV-2 infection in outpatients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic disease</measure>
    <time_frame>From baseline to 30 days of the study treatment ending</time_frame>
    <description>Evaluation of thromboembolic disease developed during the clinical course of SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen supplementation</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>Assess the need for oxygen therapy during the clinical course of the infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-Flow oxygen supplementation</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>The need for high-flow oxygen therapy during the clinical course of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>The cumulative incidence of mechanical ventilation requirement for SARS-CoV-2 infection documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracheostomy</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>The need for tracheostomy during the clinical course of SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>The need for renal replacement therapies during the clinical course of SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>The cumulative incidence of death from SARS-CoV-2 infection is documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Admission</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>The cumulative incidence of admission to intensive care for SARS-CoV-2 infection documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative hospital admission</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>The cumulative incidence of hospital admission for a documented SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization needs (days)</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>Number of days hospitalized for a SARS-CoV-2 documented infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>From baseline to the study follow-up period: Maximum 3 months</time_frame>
    <description>Serious adverse events (hospital admissions and mortality)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Micronutrient dietary supplement effervescent tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet containing:&#xD;
Retinol (Vitamin A) 700 mcg&#xD;
Cholecalciferol (Vitamin D3) 10 mcg&#xD;
Alpha-Tocopherol (Vitamin E) 45 mg&#xD;
Ascorbic acid (vitamin C) 1000 mg&#xD;
Pyridoxine (Vitamin B6) 6.5 mg&#xD;
Cyanocobalamin (Vitamin B12) 9.6 mg&#xD;
Folic acid 400 mg&#xD;
Iron 5 mg&#xD;
Zinc 10 mg&#xD;
Selenium 110 mg&#xD;
Copper 0.9 mg&#xD;
Excipients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dietary supplement effervescent tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Effervescent tablet with only the excipients.&#xD;
Sucralose 13 mg&#xD;
Sodium Chloride 20 mg&#xD;
Potassium Acesulfam 22.5 mg&#xD;
Orange P 55 mg&#xD;
Sodium Carbonate 70 mg&#xD;
Betacarotene 100 mg&#xD;
Malic Acid 800 mg&#xD;
Citric Acid 960 mg&#xD;
Sodium bicarbonate 1,000 mg&#xD;
Isomalt 1,459.50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin and trace elements</intervention_name>
    <description>Dietary supplement oral route, once a day, during 14 days</description>
    <arm_group_label>Micronutrient dietary supplement effervescent tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dietary supplement (placebo) oral route, once a day, during 14 days</description>
    <arm_group_label>Placebo dietary supplement effervescent tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed Consent Form signed.&#xD;
&#xD;
          2. Patients with symptoms compatible with COVID-19: cough and fever who not fulfil&#xD;
             criteria of hospitalization and will be in outpatient care.&#xD;
&#xD;
          3. Positive polymerase chain reaction (PCR) or transcription-mediated amplification (TMA)&#xD;
             test or rapid antigen test for severe acute respiratory syndrome Corona Virus-2&#xD;
             (SARS-CoV-2) or diagnostic test available.&#xD;
&#xD;
          4. Age ≥ 65 years.&#xD;
&#xD;
          5. Age ≥ 45 years with 1 or more comorbidities (diabetes, hypertension, obesity, heart&#xD;
             disease, respiratory disease).&#xD;
&#xD;
          6. Availability to meet the requirements of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intake of any micronutrient supplement during the month prior to inclusion.&#xD;
&#xD;
          2. Patients fulfilling hospitalization criteria.&#xD;
&#xD;
          3. Previous allergies to the micronutrient components and excipients.&#xD;
&#xD;
          4. SARS-CoV-2 completed vaccination (2 doses)&#xD;
&#xD;
          5. Age ≥ 80 years with any comorbidity (diabetes, hypertension, obesity, heart disease,&#xD;
             respiratory disease)&#xD;
&#xD;
          6. Participation in other research that requires experimental intervention (does not&#xD;
             include observational studies) in the previous month before signing the informed&#xD;
             consent form.&#xD;
&#xD;
          7. Detection by the researcher of lack of knowledge or willingness to participate and&#xD;
             comply with all the requirements of the protocol.&#xD;
&#xD;
          8. Any other findings that at the discretion of the researcher may compromise protocol&#xD;
             performance or significantly influence the interpretation or results of the effects of&#xD;
             the nutritional supplement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa M Tomasa-Irriguible, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Germans Trias i Pujol- Intensive Care Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa M Tomasa-Irriguible, MD-PhD</last_name>
    <phone>+34934978901</phone>
    <email>ttomasa.germanstrias@gencat.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana M Barriocanal, MD-PhD</last_name>
    <phone>+34934978488</phone>
    <email>ambarriocanal@igtp.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Teresa M Tomasa-Irriguible, MD-PhD</last_name>
      <phone>+34934978901</phone>
      <email>ttomasa.germanstrias@gencat.cat</email>
    </contact>
    <contact_backup>
      <last_name>Ana M Barriocanal, MD-PhD</last_name>
      <phone>+34934978488</phone>
      <email>ambarriocanal@igtp.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Eva Martínez-Cáceres, MD.PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosa Morros, MD.PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana M Barriocanal, MD.PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luisa Bordejé-Laguna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaume Barallat, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gema Fernández, MD.PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neus Robert Boter, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dietary Supplement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trace Elements</mesh_term>
    <mesh_term>Micronutrients</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

